Slides
Page 1
1 INVESTOR PRESENTATION Q2 & H1 FY27 1
Page 2
2 The Presentation is to provide the general background information about the Company’s activities as at the date of thePresentation. The information contained herein is for general information purposes only and based on estimates and should notbe considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes norepresentation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, thefairness, accuracy, completeness or correctness of any information contained herein.This presentation may include certain “forward looking statements”. These statements are based on current expectations,forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differmaterially from these statements. Important factors that could cause actual results to differ materially from our expectationsinclude, amongst others, general economic and business conditions in India and abroad, ability to successfully implement ourstrategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies,changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industriesthat we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreignexchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have anyobligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and areadvised to make their own calculations before deciding on any matter based on the information given herein.No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd. Disclaimer
Page 3
3 Table OfContents•Q2 & H1 FY27 Earnings•Company Overview•Industry Landscape•Our Competitive Advantage•Way Forward
Page 4
4 Section01Q2 & H1 FY27 Earnings•Q2 & H1 FY27 Highlights•Key Metrics: Q2 & H1 FY27•Profit & Loss Statement•Financial Track Record•Shareholding Pattern 4
Page 5
5 Q2 FY27 Highlights Rs 1,149 MnTotal Income EPSRs 4.6EBITDARs 408 Mn Margin 35.5% CAPEX (Cash Outflow)Rs 92MnPBTRs 275 Mn PATRs 206 Mn Margin 17.9%
Page 6
6 H1 FY27 Highlights Rs 2,278MnTotal Income EPSRs 9.3EBITDARs 819Mn Margin 36.0% Cash & Cash Equivalents*Rs 701MnPBTRs 559Mn PATRs 417Mn Margin 18.3% * Cash & Cash Equivalents include other bank balances
Page 7
7 Key Metrics: Q2 FY27 1,045 1,1291,149Q2FY26 Q1FY27 Q2FY274.5 4.7 4.605Q2FY26 Q1FY27 Q2FY27369 411 408 35.3%36.4%35.5%Q2FY26 Q1FY27 Q2FY27 EBIDTA EBIDTA Margin 199 210 206 19.1%18.6%17.9%Q2FY26 Q1FY27 Q2FY27 Total Income(In ₹ Mn)EBIDTA & EBIDTA Margin (In ₹ Mn, %)PAT & PAT Margin(In ₹ Mn, %)Basic EPS (In ₹)YoY3.5%YoY9.9%YoY10.5%PAT PAT Margin
Page 8
8 PAT & PAT Margin(In ₹ Mn, %)Key Metrics: H1 FY27Total Income(In ₹ Mn)EBIDTA & EBIDTA Margin (In ₹ Mn, %)Basic EPS (In ₹) 2,038 2,278 H1FY26 H1FY278.7 9.3 H1FY26 H1FY27723 819 35.5%36.0%H1FY26 H1FY27388 417 19.0%18.3%10 %15 %20 %25 %30 %35 %40 %H1FY26 H1FY27EBIDTA EBIDTA MarginPAT PAT MarginYoY11.8%YoY13.2%YoY7.3%
Page 9
9 Profit & Loss StatementYoY (%) H1 FY26H1 FY27YoY (%) Q2 FY26QoQ(%)Q1 FY27Q2 FY27Particulars (₹ Mn)1,994 2,211 1,018 1,091 1,120 Revenue from Operations44 67 27 38 29 Other Income11.8%2,038 2,278 9.9%1,045 1.8%1,129 1,149 Total Income389 488 201 226 262 Material and Testing Costs0 0 0 0 -Cost of lab setup-----Changes in inventories of work-in-progress564 601 286 294 307 Employee benefits expense361 370 189 197 173 Other expenses1,315 1,459 676 718 741 Total Expenses-----Exceptional Item13.2%723 819 10.5%369 -0.8%411 408 EBIDTA35.5%36.0%35.3%36.4%35.5%EBIDTA (%)764 24Finance costs201254102 125129Depreciation expense8.4%515559 4.8%263-2.9%283275PBT 25.3%24.5%25.1%25.1%24.0%PBT (%) 127142647369Tax 7.3%3884173.5%199-2.0%210206PAT 19.0%18.3%19.1%18.6%17.9%PAT (%) 7.0%8.79.33.4%4.5-2.1%4.74.6Basic EPS (INR)
Page 10
10 Financial Track Record 2,797 3,216 2,923 3,482 4,163 2,278 FY22 FY23 FY24 FY25 FY26 H1 FY27Total RevenueTOTAL INCOME (₹ Mn)EBITDA & EBITDA Margin PROFITABILITY (₹ Mn)PAT & PAT Margin 817 984 977 1,262 1,489 819 29%31%33%36%36%36%FY22 FY23 FY24 FY25 FY26 Q2 FY27EBIDTA EBIDTA MarginPAT PAT MarginBALANCE SHEET RATIOS RoE (%)RoCE (%) Debt to Equity Total Capex18% 17% 15% 18% 17%8%FY22 FY23 FY24 FY25 FY26 H1 FY2725% 22% 19% 23% 21%11%FY22 FY23 FY24 FY25 FY26 H1 FY270.080.050.060.020.01 0.03FY22 FY23 FY24 FY25 FY26 H1 FY27450 492 763 791 998272FY22 FY23 FY24 FY25 FY26 H1 FY27 413 482 488 668 775 417 15%15%17%19%19%18%FY22 FY23 FY24 FY25 FY26 Q2 FY27CAGR(FY22-FY26)17.0%CAGR(FY22-FY26)16.2%CAGR(FY22-FY26)10.5% 1.Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business2.CAGR for the period FY20-FY26
Page 11
11 Shareholding Pattern Promoters35.64%DII0.48%FII5.07%Others58.81% Shareholding as on 30thSeptember 2026Share Information as on 30thSeptember 2026VIMTALABSNSE Ticker524394BSE Ticker2,694.95Market Cap (INR Cr)64.36%% free-float1,734.42Free-float market cap (INR Cr)144.34Total Debt (INR Mn)701.12Cash & Cash Equivalents (INR Mn)**4,46,99,859Shares Outstanding4,05,173.043M ADTV (Shares)*24.743M ADTV (INR Cr)*TICIndustry*Source: NSE & BSE**Cash and Cash equivalents includes other bank balances
Page 12
12 Section02Company Overview•Vimta at a Glance•Our Journey•Our Offerings•Geographical Presence•Management 12
Page 13
13 Vimta at a Glance Established in1984, VIMTA is one of India’s most renowned companies for contract research andtesting, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliableservices and vast experience. The company’s broad capabilities span across biologics, small molecules,agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, andenvironment testing.42+YearsOf experience in CRTO industry~600,000Sq. Ft. of Ultra-modern lab spaces1,400+Dedicated Multi-Disciplinary Team10 Labs and Offices across India~100 Successful Regulatory Audits
Page 14
14 Our Journey 1. Investment & Revenues in INR2. Investments depicted may have spread across more than the denoted year1984199220062015 500 ft250,000+ ft2200,000+ ft2400,000+ ft2 6150+600+1000+ Minerals & ores; Metals; Rice bran oil testingEnvironment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical ResearchClinical Research; Environment; Analytical Testing –Food & PharmaAnalytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing 156,00016 M542 M1,073 M 200,00085 M992 M580 MInfrastructureCapabilitiesPeople Investment Revenues2024~600,000 ft21300+Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing3,223 M492 M
Page 15
15 Our offerings Drug discovery and development services Food, Agri & Environmental Testing Electronics & Electricals Testing
Page 16
16 1. Drug discovery and development services 16 Accreditations & Regulatory ApprovalsServicesWide range of analytical services•Microbiology•Immunogenicity studies•Characterization•Bioassays•E&L studies •Stability testing •Method development•Validations •Genotoxic impurities •Elemental analysis•In vitro studies•Physical Characterisation•Dissolution Testing•BA/BE Studies•Bioanalytical•Clinical Trials (Phase I to IV)•Clinical End Point Studies•Claim Studies•Comprehensive in vitro, ex vivo and in vivo studies •ADME, and PK •IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).•Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity•Biowaiver and alternative to animal studies•Ecotoxicology, environmental fate and metabolism studies DCA, USFDA, WHO, EMA, DRAs of Ukraine, TurkeyCDSCO, USFDA, WHO, MHRA, NPRA, and European DRAsOECD-GLP, CCSEA, DSIR, AAALACPharma Analytical Clinical Research Preclinical ResearchOfferingsPharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal HealthPharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality ChemicalsIndustry
Page 17
17 2. Biologics - Contract Research & Development Services 17 Requirements & guidelinesServicesProcess and Product Development – DS & DPSmall scale Non GMP (R&D) ICH Guidelines (Q2, Q6B, etc.) CompliantProcess Development Product DevelopmentOfferingsBiotech & BiopharmaIndustry oCell Line Development •Cell line generation•Clone screening and selection•Cell bank preparation (MCB/WCB)•Expression optimizationoUpstream Process Development•Media and feed optimization•Bioreactor process development•Scale-up studies•Process characterization oDownstream Process Development•Protein purification development•Chromatography optimization•Yield and purity improvementoAnalytical Development•Method development and validation•Protein characterization•Purity, potency, and stability testing•Glycosylation and aggregation analysis oFormulation Development•Pre-formulation studies•Liquid and lyophilized formulations•Stability studies•Container-closure compatibility
Page 18
18 3. Food, Agri & Environmental Testing 18 Accreditations & Regulatory ApprovalsServices IndustryNo. of Locations Food Manufacturing & Processing industries, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed and post project monitoring services for various industries viz., Oil & Gas, Power, Cement, Mining, Infrastructure, etc.8 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida & Kolkata)•FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board•Hyderabad Lab is a National Reference Lab for Water & Beverages Testing•Mumbai Lab is a National Food Laboratory, operated for FSSAI•MoEF, ISO 17025, QCI/NABET, OSHAS 45000 related to environmental testing services•Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all agri, food, food products, water and beverages•New product development support, validations and Shelf-life assessments•Packaging material testing•Nutraceuticals testing, method validations•Animal feed analysis•Argo-chemical (crop sciences): support for research and development, method development, validation and testing for regulatory submissions in India, Europe, South America, Japan, Southeast Asia•Post project monitoring •Industrial hygiene & Indoor air, SIA & hydrogeological studies•EHS audits, Hazardous waste study, Life cycle assessment and Due diligence studies•Green audit, Metrological studies
Page 19
19 4. Electricals & Electronics Testing & Certification 19 Accreditations & Regulatory ApprovalsServices IndustryNo. of Locations Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries 2 (Hyderabad)•NABL ISO 17025, TEC•BIS & NABCB ISO 16025•EMI/EMC testing•Radio Frequency testing•Environmental & reliability testing•Mechanical & electrical safety testing•Performance testing•Product Certification•CE marking
Page 20
20 Geographical Presence Hyderabad(Headquarters) PharmaFood & Environment Electronics & Electrical Food & Environment HyderabadAhmedabadNoidaMumbai (NFL)NashikBengaluruNelloreKolkataHyderabad Electrical and ElectronicsPharmaHyderabad
Page 21
21 Key Management Team Harita VasireddiManaging DirectorSreenivas NeerukondaExecutive DirectorS P VasireddiExecutive ChairmanHarriman VungalExecutive Director -Operations•Harita has close to 3 decades years of experience in the TIC/CRO industry with track record of growth and profitability. •Her Core competencies include management & driving organizational adaptability and development, quality management systems, and risk management. •She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India •Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.•He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India. •Dr. S P Vasireddi is a Scientist –Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.•Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc. •Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs. •He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.•He holds D. Tech in Electronics from Toronto, Canada. •Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rdrank in cost accountancy. With over 17 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management. He has previously worked at Artson Ltd. (A TATA Enterprise), Hyderabad as a CFO. Siva KambhampatiChief Financial Officer
Page 22
22 Section03Industry Landscape•Market Opportunity•Factors Driving Industry Growth 22
Page 23
23 Global(USD Mn) Markets Opportunity (Global) 10,50015,700 2026 | 20313,7005,500 2026 | 2031 2025 | 203317,96225,5812025 | 2033 Pharmaceutical Analytical TestingPreclinical Food TestingElectronics Testing 26,30048,000
Page 24
24 Indian(USD Mn) Markets Opportunity (Indian) 368780 2025 | 2035215451 2025 | 2033 2025 | 20339,19015,300 2025 | 2035 Pharmaceutical Analytical TestingPreclinical Food TestingElectronics Testing 7181,510
Page 25
25 Factors Driving Industry Growth Drug Discovery & Development Food & Environment TestingElectrical & Electronics Testing•Shift towards complex generics & biosimilars•Rising demand for innovation, biologics &peptides•India’s pharmaceutical export ambition•Growing need for specialized CRO services•Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives•Green push by Government for electrical vehicles•Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing•Increase in regulations to address the growing concerns of air, water and soil contamination
Page 26
26 Section04Our Competitive Advantage•Our Position in the CRTO Landscape•Our Strength 26
Page 27
27 Our Position in the CRTO Landscape 27 Pharma Analytical •#1 in India•Customers – 90% of India top 20•40% revenues from overseasClinical Research•Among the most reputed CROs in India•75% of revenues from overseasElectronics & Electricals•One of the leading labs in Southern IndiaFood & Environment Testing•Top 2 in India•Serving 7 of India’s top 10 food companies, large PSUs and Infra companies•The only private EU commission approved lab in IndiaPreclinical•Amongst Top 3 in India•India’s most comprehensive and integrated provider of non-clinical drug discovery and development services
Page 28
28 Our Strengths Infrastructure Compliance Innovations Knowledge TechnologyCustomer CentricityLong term partnerships with customers Unparalleled lab infrastructure in the country. Gold LEED certified VivariumFacilities with scalablecapacitiesStrong culture of quality and compliance Long & successful regulatory track record –cGMP, GLP, GCP Continuous addition of services and evolving excellenceMulti-disciplinary, skilled and trained manpower Wide range of state-of-the-art technologies and scalable capacities
Page 29
29 Section05Way Forward•Our Key Growth Drivers & Strategies 29
Page 30
30 Our Key Growth Drivers & StrategiesFavourablemarketsCore business strategiesCore operational strategiesBest practicesGrowth momentum in marketsGrowing demand for safe & quality - drugs, food, electronics & clean environmentCapacity expansionsService innovationsPenetration into new marketsCustomer partnershipsOperational excellenceHiring right talentQuality & compliance cultureCutting edge technologiesGood corporate governanceRisk managementListening to customers’ needs Continuous learning
Page 31
31 YOUTHANK Vimta Labs Ltd. Siva Kambhampati | Chief Financial OfficerSiva.Kambhampati@vimta.comErnst & YoungSiddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.Bhadekar@in.ey.comRegistered Office#142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051NSE: VIMTALABSBSE: 524394ISIN: INE579C01029Website: www.vimta.com